FAQ on Soligenix Inc.'s Advancement in Behçet’s Disease Treatment

What is Behçet’s disease?

Behçet’s disease is a rare, chronic autoimmune disorder characterized by inflammation of blood vessels, leading to symptoms like painful mouth and genital ulcers, eye inflammation, and skin lesions.

Why is Soligenix’s development of SGX945 significant?

SGX945 (dusquetide) aims to address the unmet need in treating Behçet’s disease, offering hope for patients with limited treatment options currently available.

How prevalent is Behçet’s disease?

Prevalence varies from 0.12 to 7.5 per 100,000 in the United States and Europe, but it’s more common along the Silk Road, with Türkiye having rates from 80 to 370 per 100,000.

What are the symptoms of Behçet’s disease?

Symptoms include painful mouth and genital ulcers, eye inflammation, and skin lesions, significantly affecting patients’ quality of life and productivity.

What is the current status of Soligenix’s clinical trial for SGX945?

Soligenix has initiated a clinical trial to evaluate the safety, tolerability, and preliminary efficacy of SGX945 in patients suffering from oral ulcers associated with Behçet’s disease.

Where can I find more information about Soligenix and its developments?

The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX.

Who is most affected by Behçet’s disease?

Behçet’s disease is more prevalent in countries along the Silk Road, including Türkiye, Iran, and Japan, affecting a wide range of individuals with varying severity.

What makes Behçet’s disease challenging to treat?

Even with treatment, symptoms can persist for many patients, significantly impacting their quality of life and productivity, highlighting the need for innovative therapies like SGX945.

How can I stay updated on Soligenix’s progress?

To receive SMS alerts from BioMedWire, text ‘Biotech’ to 888-902-4192 (U.S. Mobile Phones Only) or visit https://www.biomedwire.com/ for more information.